Information Provided By: 
Fly News Breaks for June 20, 2016
CRY
Jun 20, 2016 | 08:25 EDT
Canaccord said CryoLife's focus on the cardiac surgery market positions it for growth and margin expansion. The firm recently met with management and came away more bullish on its prospects for growth and upside potential and sees several medium-term catalysts that could be material to its growth picture. Canaccord reiterated its Buy rating and $14.50 price target on CryoLife shares.
News For CRY From the Last 2 Days
There are no results for your query CRY
